Patients with Post Traumatic Stress Disorder (PTSD) may soon have access to personalized
treatments thanks to a collaboration
announced Friday between Stanford Medicine and Cohen
The collaboration will examine 160 veterans who are
currently receiving psychotherapy, the go-to treatment for PTSD, to try to identify a cognitive biomarker that can help
scientists predict whether one of two types of psychotherapy will be more effective.
Post-Traumatic Stress Disorder is a psychological disorder
that arises after someone experiences or witnesses a traumatic event such as a
combat situation, natural disaster or sexual assault. About 3.5% of the U.S.
adult population has PTSD at any given time, according to the National
Institute of Mental Health.
“Not everyone who experiences a traumatic event is going to
develop the condition,” said Dr. Magali Haas, President of Cohen Veterans
Bioscience, a non-profit research organization focused on PTSD and Traumatic
Brain Injury research affecting veterans.
In many cases, two people can experience the same event and
one will develop PTSD while the other will not. Doctors have yet to determine
why this is the case. The new study may bring them closer to unlocking this
“Although it is a psychological response to a traumatic event,
it actually causes a change to the wiring of your brain,”
Haas said. “So the psychological
experience turns into a biological response that we can measure, that we can intervene
in when we finally understand those mechanisms.”
The new research is based on an earlier study by Dr. Amit
Etkin of Stanford Medicine. The details of that study are currently under
embargo while the paper is being reviewed, but Cohen Veterans Bioscience
thought them promising enough that they funded this follow-up study.
Etkin said the study may have identified a biomarker that
could help diagnose PTSD. Currently doctors have no objective test for PTSD. Instead, they rely solely on interviews with patients to diagnose the disorder. Having a
clear, measurable test could change the course of treatment, by helping doctors
identify the disease and tailor treatments to individual patients.
“We can be more objective in how we
assess the disease in the first place so whether someone has it or not,” Haas
said. “We’ll hopefully develop better tests that are objective tests that say
yes you have the condition or you don’t, much the same way we measure whether
you have a virus.”
Under the new study, patients who have
been diagnosed with PTSD will be compared against a control of healthy patients
with the goal of replicating Etkin’s initial results.
“What we’re looking for is a signature in
their brain essentially, a descriptor of how different parts of their brain function
together that tells us how efficient their brain is at processing information,”
Etkin said. “Imagine it’s like an orchestra. An orchestra needs to work
together, work in unison, to make the music sound good … Whose brain is making
good sounding music and whose brain is falling apart?”
Like most psychological disorders, PTSD can manifest in many ways. Thus far,
doctors have had no way of telling one type of PTSD from another. As a result,
patients receive standardized treatments that may not help them.
“The idea, furthermore, is that if you
don’t have the right treatment for that subtype, you are giving either an
ineffective or potentially harmful treatment to somebody who’s not going to
respond,” Etkin said. “You realize just how strange our current approach is,
which is this one-size-fits-all approach, which we know is not optimal but
we’ve not yet had the tools to go beyond it.”
Etkin’s early research investigated
female civilians who had experienced sexual assault, car accidents, violent
crimes or other traumatic situations. The new research will look at veterans.
“It happens that veterans are both an
important population to study, but also an ideal context for trying to make the
bridge to the real world and real world clinics because the VA has really done
a wonderful job in rolling out standardized treatments,” Etkin said.
If the new study successfully replicates
and expands upon Etkin’s earlier results, Cohen Veterans Bioscience would work
to develop a definitive diagnostic test and get it approved for commercial use,
“The reality is to understand it as you
understand any chronic medical condition, like diabetes, like high blood pressure
that leads to problems,” Etkin said. “PTSD is exactly like that, it’s a chronic
condition that has no cure and it’s biological in its basis, though
psychological in its experience. You have to find the right intervention for
the person and without that there’s some very bad outcomes.”
Thanks for being here and being a loyal reader. The American Media Institute covers stories other news outlets do not. We recruit reporters all over the world, investing money in translators, travel and document research. We are not a blog, which has few expenses beyond pajamas. Please help us continue to provide hard-hitting journalism by making a tax-deductible contribution today. Thank you.